• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series.

作者信息

Ogbutor Chino, Chen Li-Chi, Kalil Luiza L, Kelley Kristen J, Craiglow Brittany G, King Brett, Senna Maryanne Makredes

机构信息

Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts.

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.

出版信息

Int J Womens Dermatol. 2025 Aug 13;11(3):e218. doi: 10.1097/JW9.0000000000000218. eCollection 2025 Oct.

DOI:10.1097/JW9.0000000000000218
PMID:40810112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12348381/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8485/12348381/86709e235c87/jw9-11-e218-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8485/12348381/86709e235c87/jw9-11-e218-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8485/12348381/86709e235c87/jw9-11-e218-g001.jpg

相似文献

1
Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series.斑秃患者因妊娠停用及重新启用 Janus 激酶抑制剂：病例系列报道
Int J Womens Dermatol. 2025 Aug 13;11(3):e218. doi: 10.1097/JW9.0000000000000218. eCollection 2025 Oct.
2
Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.评估斑秃的现有和新型JAK抑制剂：一项叙述性综述
Dermatol Ther (Heidelb). 2025 Aug 12. doi: 10.1007/s13555-025-01517-9.
3
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata.口服酪氨酸激酶3/肝细胞癌中表达的酪氨酸激酶家族激酶抑制剂芦可替尼24个月的疗效和安全性：斑秃的ALLEGRO IIb/III期和长期III期临床研究的综合分析
Br J Dermatol. 2025 Jan 24;192(2):215-227. doi: 10.1093/bjd/ljae365.
4
The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients.JAK 抑制剂治疗斑秃的疗效和安全性评价：2018 例患者的系统评价和荟萃分析。
Front Immunol. 2023 Jun 2;14:1195858. doi: 10.3389/fimmu.2023.1195858. eCollection 2023.
5
Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.成人斑秃治疗新药的系统评价：Janus 激酶抑制剂、生物制剂和磷酸二酯酶 4 抑制剂。
J Eur Acad Dermatol Venereol. 2023 Apr;37(4):666-679. doi: 10.1111/jdv.18810. Epub 2022 Dec 22.
6
Therapeutic management in paediatric alopecia areata: A systematic review.儿童斑秃的治疗管理：系统评价。
J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1299-1308. doi: 10.1111/jdv.17187.
7
Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis.JAK 抑制剂治疗儿童斑秃的疗效和安全性：系统评价和荟萃分析。
J Dermatolog Treat. 2022 Dec;33(8):3143-3149. doi: 10.1080/09546634.2022.2133956. Epub 2022 Oct 13.
8
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment.在两项III期试验中，巴瑞替尼治疗重度斑秃成人患者长达4年（中位治疗时间2.3年）的安全性。
Am J Clin Dermatol. 2025 Apr 11. doi: 10.1007/s40257-025-00932-0.
9
Treatment of pediatric alopecia areata: A systematic review.儿童斑秃的治疗：系统评价。
J Am Acad Dermatol. 2022 Jun;86(6):1318-1334. doi: 10.1016/j.jaad.2021.04.077. Epub 2021 Apr 30.
10
Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study.约旦患者中 Janus 激酶抑制剂治疗脱发的疗效：一项回顾性队列研究。
Cureus. 2025 May 18;17(5):e84321. doi: 10.7759/cureus.84321. eCollection 2025 May.

本文引用的文献

1
Current evidence on safety of Janus kinase inhibitors in pregnancy and lactation.
J Am Acad Dermatol. 2025 May;92(5):1082-1084. doi: 10.1016/j.jaad.2024.10.108. Epub 2024 Dec 3.
2
The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity.斑秃的负担：一项聚焦于生活质量、心理健康和工作效率的范围综述。
J Eur Acad Dermatol Venereol. 2023 Jan 27. doi: 10.1111/jdv.18926.
3
Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial.在一项2a期随机临床试验的单盲扩展试验中，对斑秃患者使用利特昔替尼和布雷西替尼进行维持、撤药及再治疗。
J Am Acad Dermatol. 2022 Aug;87(2):390-393. doi: 10.1016/j.jaad.2021.12.008. Epub 2021 Dec 13.
4
Alopecia areata: a review of disease pathogenesis.斑秃：疾病发病机制的综述。
Br J Dermatol. 2018 Nov;179(5):1033-1048. doi: 10.1111/bjd.16808. Epub 2018 Sep 9.
5
Assessing quality of life in Alopecia areata patients in China.评估中国斑秃患者的生活质量。
Psychol Health Med. 2015;20(1):97-102. doi: 10.1080/13548506.2014.894641. Epub 2014 Mar 17.